Please login to the form below

Not currently logged in
Email:
Password:

Kisqali

This page shows the latest Kisqali news and features for those working in and with pharma, biotech and healthcare.

NICE gives Lilly’s Verzenios chance to compete with rivals

NICE gives Lilly’s Verzenios chance to compete with rivals

Novartis’ Kisqali (ribociclib) is far behind Pfizer’s drug (but expected to hit $1.6bn in 2022 according to EvaluatePharma), with Verzenios expected to give Kisquali competition for second place in ... However, analysts says Verzenios has an

Latest news

More from news
Approximately 6 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics